Celldex Therapeutics: Promising Phase 1b Results For Barzolvolimab In CSU (NASDAQ:CLDX)

Celldex Therapeutics (NASDAQ:CLDX), an American biotech company, primarily focuses on the development and commercialization of novel therapeutic candidates for the treatment of several diseases. With a robust pipeline of drug candidates, the company is poised to make significant strides in the biopharma industry.

Celldex has pioneered many therapeutic approaches that have the potential to yield significant clinical benefits. While one must bear in mind that biopharmaceuticals carry inherent risks related to clinical trials and regulatory approvals, Celldex’s scientific acumen and strategic direction seem to be paving the way for promising advances in the sector.

Financials

From the start of Q2 to its end in 2023, Celldex observed a reduction in its cash position from $278.4 million to $252.7 million, marking a quarterly cash burn of $25.7 million. Accounting for the mentioned net sales and maturities of marketable securities at $1.6 million, the net cash used for operating activities stands at $27.2 million. Given this burn rate, assuming no additional revenues or funding, and no escalation in expenses, the cash reserves would theoretically last for roughly 9 quarters or a little over 2 years – Celldex itself anticipates that its current financial resources are ample to cover operational costs until 2025.

A marked year-over-year growth in revenue is evident. Celldex’s revenue for the first half of 2023 stands at $1.2 million, showing a quadruple increment compared to the first half of 2022 at $0.3 million. This surge is attributed mainly to the enhanced services rendered under agreements with Rockefeller University. Yet, the absolute revenue figures remain relatively modest in the grand scheme of the company’s financial landscape.

Research and development continue to be a significant expenditure for Celldex, indicating their dedication to pushing the boundaries of their drug pipeline. The expenses related to R&D have seen a noticeable hike, especially in areas like the barzolvolimab clinical trial and its contract manufacturing. While increased R&D expenses can be a sign of active development and potential future growth, they also underscore the importance of these projects reaching fruitful endpoints to justify the investment.

General and administrative expenses have remained relatively stable when comparing the figures from 2022 and 2023. The slight reduction in these expenses in the first half of 2023 is primarily from trimmed legal expenses, balanced out by increased stock-based compensation.

The reported gain from the remeasurement in 2022 due to deprioritizing the CDX-1140 program highlights an important strategic shift for the company. Such decisions might lead to short-term financial gains but could also signal a recalibration of long-term strategies.

Celldex reported a net loss of $30.5 million for Q2 2023, showing a reduction when juxtaposed with the $36.0 million loss from Q2 2022. Similarly, the first half of 2023 had a comparable net loss to that of 2022, even with increased R&D expenses. This hints at the company’s ability to manage its resources while pursuing aggressive research undertakings.

Pipeline

Celldex is actively working on the development of novel therapeutic candidates, with Barzolvolimab and CDX-585 being the primary drivers.

Barzolvolimab is a humanized monoclonal antibody developed for the treatment of chronic urticaria, an affliction characterized by recurrent hives and itching. This antibody works by binding to and inhibiting the KIT receptor’s activity, which is found in mast cells and is responsible for triggering inflammatory responses like hypersensitivity and allergies. The antibody has demonstrated positive results in Phase 1b studies for patients with chronic spontaneous urticaria (CSU) and cholinergic urticaria (CIndU), significantly reducing the severity and frequency of hives while improving the patients’ quality of life.

Currently, Barzolvolimab is in Phase 2 clinical trials for CSU, cold urticaria (ColdU), and symptomatic dermographism (SD), with Celldex expecting to complete enrollment by Q3 2023 and report topline data late 2023 or early 2024. However, there could be setbacks in the form of patient recruitment slowdown or unforeseen safety signals that could delay these plans. Furthermore, the company plans to initiate Phase 2 studies for eosinophilic esophagitis and prurigo nodularis, which may benefit from Barzolvolimab’s mechanism of action.

Another intriguing product is CDX-585, a bispecific antibody that targets PD-1 and TIM-3 simultaneously, two immune checkpoints that suppress anti-tumor immune responses. By enhancing T cell activity and overcoming resistance to PD-1 blockade therapy, CDX-585 could be instrumental in the treatment of solid tumors. The drug has successfully completed GMP manufacturing and IND-enabling studies and is expected to enter clinical trials in mid-2023 for patients with advanced malignancies. However, this product also holds potential risks, particularly because bispecific antibodies are relatively new entrants in the field of immuno-oncology and can carry unknown challenges, both from a clinical and a manufacturing perspective. CDX-585’s effectiveness in overcoming resistance to PD-1 therapies is not guaranteed and will need to be confirmed through rigorous clinical testing. The projected initiation of clinical trials in mid-2023 could also face unforeseen regulatory or logistical delays.

Barzolvolimab Excels in Chronic Urticaria Trials

The recent Phase 1b multi-dose clinical trial results presented at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2023 further strengthen the potential of Celldex’s flagship candidate, barzolvolimab, in treating chronic urticarias.

The data from these trials indicate that barzolvolimab is not just a novel therapeutic approach but has proven to be effective in the treatment of CSU and CIndU. The drug’s mode of action, specifically inhibiting the receptor tyrosine kinase KIT, which is crucial for mast cell function, brings a refreshing perspective to the field, as it continues to demonstrate consistent symptom improvement.

The robustness of the clinical trial results seems to lie in the observation of mast cell depletion by barzolvolimab. Symptom improvement was seen to correspond with tryptase suppression, a marker of mast cell activation, suggesting a mechanistic link between the drug’s activity and the clinical benefits observed.

The CSU study revealed a fascinating aspect, showing significant improvements in angioedema, a distressing manifestation of urticaria in many patients. CSU is typically marked by prolonged episodes of hives or wheals without identifiable triggers, often accompanied by Angioedema. The latter is particularly debilitating as it usually results in swelling in various parts of the body. The study’s results are encouraging, showing barzolvolimab’s ability to cause a considerable improvement in angioedema symptoms, which was sustained across all dose levels tested.

This data, coupled with the fact that a majority of barzolvolimab-treated patients remained free of angioedema symptoms at weeks 12 and 24, reinforces the drug’s potential as a new treatment option for patients who are not finding relief with existing treatments. Furthermore, the drug’s strong safety profile and high tolerance levels add to its potential value.

On a broader scale, the success of barzolvolimab in these trials supports its ongoing Phase 2 studies. If the promising Phase 1b results are any indication, the upcoming Phase 2 CSU study could further bolster Celldex’s position in the chronic urticaria treatment market. With topline data expected by the end of this year, investors and patients alike will be keenly watching Celldex’s progress.

Navigating Risks in Barzolvolimab Development

Firstly, there’s the risk of off-target effects. Although barzolvolimab has been engineered to bind to the KIT receptor with high specificity, the possibility of binding to other targets, leading to undesired side effects, cannot be completely ruled out. Detailed studies of the drug’s specificity and the potential for off-target binding are crucial.

Secondly, the long-term effects of sustained inhibition of KIT activity, which is fundamental to mast cell function, are not yet fully known. While the short-term benefits in treating urticaria have been observed, long-term use could potentially have adverse consequences, including an impact on the immune response. This underscores the importance of carefully monitoring long-term study participants.

Another inherent risk lies in the development of resistance to the drug. There’s a possibility that with time, mast cells may evolve mechanisms to bypass the inhibition of KIT, rendering the drug less effective. Understanding this possibility will require ongoing, post-approval surveillance of patients.

There’s also a risk associated with individual variation in patient responses. It is commonplace in clinical practice to observe varied responses to the same drug across the patient population. This variability can be due to multiple factors, including genetics, co-morbid conditions, concurrent medications, among others. Hence, despite the drug’s current efficacy, it may not be equally effective for all patient subsets.

Finally, while the safety profile of barzolvolimab is encouraging, the occurrence of unexpected adverse events in larger, more diverse patient populations remains a possibility. This factor emphasizes the need for vigilance in tracking and reporting safety data as the drug moves further along the development process and is eventually marketed.

Competitors

Several other companies are operating in the same space as Celldex, each with its own promising therapies. However, none appear to match the unique potential of Celldex’s barzolvolimab, both in terms of their approach to treatment and the preliminary results.

Novartis (NVS), for instance, markets Xolair (omalizumab), an anti-IgE antibody, which is currently the standard of care for CSU patients who don’t respond to antihistamines. However, a significant subset of CSU patients do not achieve symptom control even with omalizumab, revealing a significant unmet need that barzolvolimab aims to address. Furthermore, omalizumab’s efficacy is often confined to the period of administration, and symptoms may reoccur once treatment is discontinued. This stands in contrast to barzolvolimab, which has demonstrated durable and prolonged symptom control.

AstraZeneca (AZN) has tezepelumab, an antibody that blocks the action of thymic stromal lymphopoietin (TSLP), an epithelial cytokine implicated in various allergic diseases, including CSU. However, while tezepelumab’s mechanism of action is novel, it doesn’t address the fundamental role of mast cells in CSU, as barzolvolimab does.

Lilly’s Olumiant (LLY) (baricitinib) , a Janus kinase (JAK) inhibitor, is being explored in the treatment of CSU. While JAK inhibitors can be potent immunomodulators, their broad immunosuppressive effects raise safety concerns, especially with long-term use. In contrast, barzolvolimab’s targeted approach to mast cells holds the promise of effective treatment with a potentially better safety profile.

Lastly, there’s Galderma’s nemolizumab, an anti-IL-31 receptor A monoclonal antibody, which has shown efficacy in reducing itch, a predominant symptom in CSU. While promising, it primarily addresses symptomatic relief and doesn’t directly target the underlying disease pathophysiology, potentially limiting its overall effectiveness in treating CSU.

Valuation and Takeaways

The valuation of Celldex reveals some significant indicators that must be weighed against the backdrop of the company’s promising future potential. At present, Celldex is trading at a market cap of $1.5 billion, reflecting a price-to-book ratio of 5.20 based on its TTM revenue. It’s worth acknowledging that this ratio is much higher than the average P/B ratio of 2.13 for the sector. Though at first glance, this disparity may indicate an inflated valuation, it can also be viewed as a market acknowledgment of the underlying growth prospects that distinguish Celldex from its peers.

The quadrupling of revenue for the first half of 2023, as compared to the previous year, represents a notable surge. This momentum, primarily driven by enhanced services rendered under agreements with Rockefeller University, augments the validity of the higher P/B ratio. Also, the development of promising therapeutic candidates like Barzolvolimab and CDX-585 signifies an innovative and forward-looking strategy. The successful progress of Barzolvolimab in treating chronic urticarias, paired with an aggressive yet carefully managed R&D plan, amplifies the potential for longer-term revenue growth.

As with any company in the biotech sector, caution should be exercised. Celldex faces potential setbacks such as regulatory hurdles, drug development risks, and intense competition in the oncology space. Despite these challenges, Celldex’s diversified pipeline and the demonstrated efficacy of Barzolvolimab mark it as a company to watch closely.